HT
RARE icon

Headlands Technologies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Headlands Technologies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
50,800
+22,593
+80% +$509K 0.12% 194
2025
Q4 		$649K Buy
28,207
+2,778
+11% +$91.4K 0.05% 351
2025
Q3 		$765K Buy
25,429
+13,446
+112% +$403K 0.06% 283
2025
Q2 		$436K Buy
11,983
+10,360
+638% +$373K 0.05% 335
2025
Q1 		$58.8K Buy
+1,623
New +$67.5K 0.01% 679
2024
Q4 		– Sell
-12,052
Closed -$669K – 1511
2024
Q3 		$669K Buy
12,052
+5,928
+97% +$302K 0.08% 282
2024
Q2 		$252K Buy
6,124
+5,530
+931% +$236K 0.03% 418
2024
Q1 		$27.7K Buy
+594
New +$28K 0.01% 843
2023
Q4 		– Sell
-3,351
Closed -$119K – 1236
2023
Q3 		$119K Buy
3,351
+1,127
+51% +$44.7K 0.06% 269
2023
Q2 		$103K Buy
2,224
+2,186
+5,753% +$101K 0.03% 382
2023
Q1 		$1.52K Buy
+38
New +$1.63K ﹤0.01% 441

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Headlands Technologies's RARE Position: Q1 2026 in Review

Headlands Technologies increased its Ultragenyx Pharmaceutical (RARE) stake by 80% in Q1 2026, buying an estimated $509K and bringing the position to 50,800 shares worth $1.06M. The position accounts for 0.12% of the portfolio, ranked #194.

Headlands Technologies first reported a position in RARE in Q1 2023 and has held it in 11 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Headlands Technologies held 50,800 shares of Ultragenyx Pharmaceutical worth $1.06M as of Q1 2026.
  • Headlands Technologies bought 22,593 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $509K.
  • Ultragenyx Pharmaceutical made up 0.12% of Headlands Technologies's portfolio in Q1 2026, its #194 holding.
  • Headlands Technologies first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and has held it in 11 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.